DK2941269T3 - Terapeutiske vacciner til behandling af herpes simplex-virus type 2-infektioner - Google Patents
Terapeutiske vacciner til behandling af herpes simplex-virus type 2-infektioner Download PDFInfo
- Publication number
- DK2941269T3 DK2941269T3 DK14735408.8T DK14735408T DK2941269T3 DK 2941269 T3 DK2941269 T3 DK 2941269T3 DK 14735408 T DK14735408 T DK 14735408T DK 2941269 T3 DK2941269 T3 DK 2941269T3
- Authority
- DK
- Denmark
- Prior art keywords
- infections
- treatment
- herpes simplex
- simplex virus
- virus type
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/035—Herpes simplex virus I or II
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361749682P | 2013-01-07 | 2013-01-07 | |
US201361799552P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/010516 WO2014107731A1 (en) | 2013-01-07 | 2014-01-07 | Therapeutic vaccines for treating herpes simplex virus type 2 infections |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2941269T3 true DK2941269T3 (da) | 2021-01-11 |
Family
ID=51061129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14735408.8T DK2941269T3 (da) | 2013-01-07 | 2014-01-07 | Terapeutiske vacciner til behandling af herpes simplex-virus type 2-infektioner |
Country Status (9)
Country | Link |
---|---|
US (2) | US9566325B2 (da) |
EP (1) | EP2941269B1 (da) |
JP (2) | JP6469585B2 (da) |
AU (2) | AU2014203873A1 (da) |
CA (1) | CA2897398A1 (da) |
DK (1) | DK2941269T3 (da) |
ES (1) | ES2847930T3 (da) |
HK (1) | HK1216988A1 (da) |
WO (1) | WO2014107731A1 (da) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014164699A1 (en) * | 2013-03-11 | 2014-10-09 | The Regents Of The University Of California | Herpes virus vaccines and treatments |
WO2018186755A1 (en) * | 2017-04-04 | 2018-10-11 | Beagley Kenneth | Novel vaccine for the prevention or treatment of an infection caused by a herpes virus. |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
US4426330A (en) | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
US5171568A (en) | 1984-04-06 | 1992-12-15 | Chiron Corporation | Recombinant herpes simplex gb-gd vaccine |
US5612041A (en) | 1984-07-17 | 1997-03-18 | Chiron Corporation | Recombinant herpes simplex gD vaccine |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
GB8819209D0 (en) | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
GB8824593D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Liposomes |
US4999403A (en) | 1988-10-28 | 1991-03-12 | Exxon Chemical Patents Inc. | Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions |
JP3237842B2 (ja) | 1988-12-16 | 2001-12-10 | オランダ国 | ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン |
US5290563A (en) | 1989-07-27 | 1994-03-01 | Laboratoire Des Stallergenes | Method for combining a mixture of heterogeneous substances with liposomes |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5356633A (en) | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
GB9105992D0 (en) | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
DK0614465T3 (da) | 1991-11-16 | 1999-09-27 | Smithkline Beecham Biolog | Hybridprotein mellem CS fra Plasmodium og HBsAg |
JP3351476B2 (ja) | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | リン脂質誘導体及びそれを含有するリポソーム |
US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
CA2137297C (en) | 1993-12-06 | 2000-04-18 | Tsuyoshi Miyazaki | Reactive vesicle and functional substance-fixed vesicle |
US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
KR100619350B1 (ko) | 1997-07-21 | 2006-09-05 | 박스터 헬쓰케어 에스.에이. | 변형 면역성 뉴멀리신 백신조성물 |
US7459524B1 (en) | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
BR9814912A (pt) | 1997-11-28 | 2000-10-03 | Genset Sa | Sequência genÈmica e polipeptìdeos de chlamydia trachomatis, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
HUP0101047A3 (en) | 1998-03-09 | 2004-10-28 | Smithkline Beecham Biolog | Combined vaccine compositions |
CN1629185B (zh) | 1998-04-07 | 2011-11-02 | 科里克萨公司 | 结核杆菌抗原融合蛋白及其应用 |
WO1999063063A1 (en) | 1998-06-03 | 1999-12-09 | Northwestern University | Cellular proteins which mediate herpesvirus entry |
WO2000011140A1 (en) | 1998-08-20 | 2000-03-02 | The Wistar Institute Of Anatomy And Biology | Methods of augmenting mucosal immunity through systemic priming and mucosal boosting |
US6692752B1 (en) | 1999-09-08 | 2004-02-17 | Smithkline Beecham Biologicals S.A. | Methods of treating human females susceptible to HSV infection |
WO2000076476A1 (en) * | 1999-06-11 | 2000-12-21 | Endorex Corporation | Adjuvant-containing polymerized liposomes for oral, mucosal or intranasal vaccination |
JP2003517042A (ja) | 1999-12-17 | 2003-05-20 | アメリカン・サイアナミド・カンパニー | 単純ヘルペスウイルスワクチンに対する免疫応答を強化する方法 |
US20030072794A1 (en) * | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
US20030008000A1 (en) | 2001-03-08 | 2003-01-09 | Wong Jonathan P. | DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus |
US7314624B2 (en) * | 2001-06-05 | 2008-01-01 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
US20060110736A1 (en) | 2002-10-07 | 2006-05-25 | John Donnelly | Hiv vaccine formulations |
WO2005067966A1 (en) * | 2004-01-07 | 2005-07-28 | Biomedical Research Models, Inc. | Methods for tailoring the immune response to an antigen or immunogen |
CA2658484A1 (en) | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions and methods for vaccinating against hsv-2 |
US8865185B2 (en) | 2006-09-08 | 2014-10-21 | The Trustees Of The University Of Pennsylvania | Methods of use for HSV-1 and HSV-2 vaccines |
CN101583381B (zh) | 2006-09-08 | 2014-05-07 | 宾夕法尼亚大学董事会 | Hsv-1和hsv-2疫苗和其使用方法 |
EP2507259B1 (en) | 2009-12-05 | 2016-08-24 | Ruprecht-Karls-Universität Heidelberg | Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins |
DK2544693T3 (da) * | 2010-03-09 | 2017-12-04 | Biomedical Res Models Inc | Hidtil ukendt tilgang til vaccination gennem slimhinder mod herpes simplex-virus type-2 |
-
2014
- 2014-01-07 US US14/149,670 patent/US9566325B2/en active Active
- 2014-01-07 EP EP14735408.8A patent/EP2941269B1/en active Active
- 2014-01-07 CA CA2897398A patent/CA2897398A1/en not_active Abandoned
- 2014-01-07 AU AU2014203873A patent/AU2014203873A1/en not_active Abandoned
- 2014-01-07 ES ES14735408T patent/ES2847930T3/es active Active
- 2014-01-07 JP JP2015551837A patent/JP6469585B2/ja not_active Expired - Fee Related
- 2014-01-07 WO PCT/US2014/010516 patent/WO2014107731A1/en active Application Filing
- 2014-01-07 DK DK14735408.8T patent/DK2941269T3/da active
-
2016
- 2016-04-28 HK HK16104903.0A patent/HK1216988A1/zh unknown
-
2017
- 2017-09-22 US US15/713,019 patent/US20180008695A1/en not_active Abandoned
-
2018
- 2018-05-28 JP JP2018101367A patent/JP6684309B2/ja not_active Expired - Fee Related
- 2018-09-24 AU AU2018236682A patent/AU2018236682B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
JP6469585B2 (ja) | 2019-02-13 |
HK1216988A1 (zh) | 2016-12-16 |
AU2014203873A1 (en) | 2015-07-30 |
JP2018131461A (ja) | 2018-08-23 |
US20180008695A1 (en) | 2018-01-11 |
EP2941269B1 (en) | 2020-12-09 |
CA2897398A1 (en) | 2014-07-10 |
JP6684309B2 (ja) | 2020-04-22 |
ES2847930T3 (es) | 2021-08-04 |
US20140193483A1 (en) | 2014-07-10 |
AU2018236682B2 (en) | 2020-04-30 |
AU2018236682A1 (en) | 2018-10-11 |
JP2016505622A (ja) | 2016-02-25 |
US9566325B2 (en) | 2017-02-14 |
EP2941269A4 (en) | 2016-08-17 |
WO2014107731A1 (en) | 2014-07-10 |
EP2941269A1 (en) | 2015-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46024A (fr) | Vaccin contre le virus de l'herpès simplex | |
MA49463A (fr) | Vaccin contre le virus de l'herpès simplex | |
IL263972A (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
DK3349758T3 (da) | Fremgangsmåder til behandling af arenaviridae-virusinfektioner | |
HK1216421A1 (zh) | 用於治療病毒感染的治療化合物 | |
DK3245206T3 (da) | Pyrazinforbindelser til behandling af infektionssygdomme | |
MA46317A (fr) | Vaccin contre le virus respiratoire syncytial | |
HK1213569A1 (zh) | 用於治療病毒性感染的 -氨基嘧啶衍生物 | |
BR112015002524A2 (pt) | derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças. | |
DK3328880T3 (da) | Terapeutiske midler | |
DK3043865T3 (da) | Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion | |
DK3068392T5 (da) | Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme | |
DK2903967T6 (da) | Acylaminopyrimidinderivater til behandling af virusinfektioner og andre sygdomme | |
DK3033086T3 (da) | Kombinationsterapi til behandling af cancer | |
DK3036258T3 (da) | Immunreceptormodulering til behandling af cancer og virusinfektioner | |
DK2852391T3 (da) | Systemer til behandling af lungeinfektioner | |
DK3311824T3 (da) | Cd47 målrettede terapier til behandlingen af infektionssygdomme | |
DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
DK3213750T3 (da) | Kombination af to antivirale midler til behandling af hepatitis c | |
LT3405466T (lt) | Arilu pakeistieji pirimidinai, skirti naudoti gripo viruso infekcijos atveju | |
DK3436074T3 (da) | Thiazolidforbindelser til behandling af virale infektioner | |
IL256327A (en) | Pharmacological preparations for the treatment of viral problems of the eye | |
DK2961426T3 (da) | Behandling af sygdomme i centralnervesystemet ved intranasal indgivelse af immunoglobulin g | |
DK3452100T3 (da) | FARMACEUTISKE BÆRERE INDEHOLDENDE miRNAer TIL ANVENDELSE I BEHANDLINGEN AF FIBROTISKE SYGDOMME FORÅRSAGET AF HYPERGLYKÆMI | |
DK3125874T3 (da) | Et terapeutisk middel til anvendelse i behandlingen af infektioner |